Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Hospital-acquired pneumonia cost-effectiveness of therapy
Introduction
Overview
Overview
Linezolid was compared to vancomycin for the treatment of VAP, and showed cost-effectiveness as an alternative to vancomycin treatment as it had a higher cure rate and prices per treatment were similar.[1][2] One study reported that oropharingeal decontamination decreased the incidence of ventilator-associated pneumonia from 4% to less than 1% in the studied population. The cost of the intervention was less than $2500. [3]
References
References
- ↑ Shorr AF, Susla GM, Kollef MH (2004). “Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin”. Crit Care Med. 32 (1): 137–43. doi:10.1097/01.CCM.0000104110.74657.25. PMID 14707572.
- ↑ De Cock E, Krueger WA, Sorensen S, Baker T, Hardewig J, Duttagupta S; et al. (2009). “Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany”. Infection. 37 (2): 123–32. doi:10.1007/s15010-008-8046-7. PMID 19277465.
- ↑ van Nieuwenhoven CA, Buskens E, Bergmans DC, van Tiel FH, Ramsay G, Bonten MJ (2004). “Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units”. Crit Care Med. 32 (1): 126–30. doi:10.1097/01.CCM.0000104111.61317.4B. PMID 14707570.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]